Nanoparticle targeting of anti-cancer drugs that alter intracellular signaling or influence the tumor microenvironment

Advanced Drug Delivery Reviews

Volumn 79, Issue , 2014, Pages 107-118

  Kanapathipillai, Mathumai ^a   Brock, Amy ^b   Ingber, Donald E ^a,c,d  

^a HARVARD UNIVERSITY   (United States)

^b The University of Texas at Austin   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d HARVARD UNIVERSITY   (United States)

Author keywords

Delivery; Drug; Microenvironment; Nanoparticle; Nanotherapeutics; Tumor

Indexed keywords

CONTROLLED DRUG DELIVERY; DISEASES; NANOPARTICLES; SIGNAL TRANSDUCTION; TUMORS;

DELIVERY; DRUG; INTRACELLULAR SIGNALING; MICROENVIRONMENTS; NANOPARTICLE TARGETING; NANOPARTICLE TECHNOLOGIES; NANOTHERAPEUTICS; TUMOR MICROENVIRONMENT;

TARGETED DRUG DELIVERY;

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CHITOSAN; CYANOACRYLATE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FOLIC ACID; HYALURONIC ACID; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 12; NANOPARTICLE; PACLITAXEL; POLYETHYLENEIMINE; POLYGLACTIN; PROTEIN LYSINE 6 OXIDASE; PROTEOGLYCAN; QUANTUM DOT; SMALL INTERFERING RNA; TAMOXIFEN; TRANSFERRIN; TRANSFORMING GROWTH FACTOR ALPHA; TRASTUZUMAB; VASCULAR CELL ADHESION MOLECULE 1;

ANTIGEN BINDING; BINDING AFFINITY; BIODEGRADATION; CANCER CELL; CARCINOGENESIS; CELL DIFFERENTIATION; CELL INTERACTION; CELL MEMBRANE; CELL PROLIFERATION; CELL SURVIVAL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG TARGETING; EHRLICH ASCITES TUMOR; ENDOCYTOSIS; EXTRACELLULAR MATRIX; GLIOMA; HUMAN; HYPOXIA; IMMUNE RESPONSE; IMMUNOREACTIVITY; MELANOMA; MITOCHONDRIAL MEMBRANE; MOLECULAR RECOGNITION; NANOTECHNOLOGY; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PROSTATE CANCER; PROTEIN CROSS LINKING; REVIEW; RNA DEGRADATION; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; TUMOR VOLUME; TUMOR XENOGRAFT; VASCULAR ENDOTHELIUM; ANIMAL; DRUG EFFECTS; NEOPLASMS; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; NANOPARTICLES; NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84919642689     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2014.05.005     Document Type: Review

References (149)

1. Lammers T., Kiessling F., Hennink W.E., Storm G. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J. Control. Release 2012, 161:175-187.
2. Ding Y., Li S., Nie G. Nanotechnological strategies for therapeutic targeting of tumor vasculature. Nanomedicine (London) 2013, 8:1209-1222.
3. Nie S., Xing Y., Kim G.J., Simons J.W. Nanotechnology applications in cancer. Annu. Rev. Biomed. Eng. 2007, 9:257-288.
4. Alexis F., Pridgen E.M., Langer R., Farokhzad O.C. Nanoparticle technologies for cancer therapy. Handb. Exp. Pharmacol. 2010, 55-86.
5. Allen T.M. Ligand-targeted therapeutics in anticancer therapy. Nat. Rev. Cancer 2002, 2:750-763.
6. Ozcelikkale A., Ghosh S., Han B. Multifaceted transport characteristics of nanomedicine: needs for characterization in dynamic environment. Mol. Pharm. 2013, 10:2111-2126.
7. Rizzo L.Y., Theek B., Storm G., Kiessling F., Lammers T. Recent progress in nanomedicine: therapeutic, diagnostic and theranostic applications. Curr. Opin. Biotechnol. 2013, 24:1159-1166.
8. Matsumura Y., Kataoka K. Preclinical and clinical studies of anticancer agent-incorporating polymer micelles. Cancer Sci. 2009, 100:572-579.
9. Gradishar W.J., Tjulandin S., Davidson N., Shaw H., Desai N., Bhar P., Hawkins M., O'Shaughnessy J. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J. Clin. Oncol. 2005, 23:7794-7803.
10. Hofheinz R.D., Gnad-Vogt S.U., Beyer U., Hochhaus A. Liposomal encapsulated anti-cancer drugs. Anticancer Drugs 2005, 16:691-707.
11. Danhier F., Feron O., Preat V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J. Control. Release 2010, 148:135-146.
12. Decuzzi P., Lee S., Bhushan B., Ferrari M. A theoretical model for the margination of particles within blood vessels. Ann. Biomed. Eng. 2005, 33:179-190.
13. Tiwari M. Nano cancer therapy strategies. J. Cancer Res. Ther. 2012, 8:19-22.
14. Allen T.M., Sapra P., Moase E., Moreira J., Iden D. Adventures in targeting. J. Liposome Res. 2002, 12:5-12.
15. Alexis F., Rhee J.W., Richie J.P., Radovic-Moreno A.F., Langer R., Farokhzad O.C. New frontiers in nanotechnology for cancer treatment. Urol. Oncol. 2008, 26:74-85.
16. Perry J.L., Herlihy K.P., Napier M.E., Desimone J.M. PRINT: a novel platform toward shape and size specific nanoparticle theranostics. Acc. Chem. Res. 2011, 44:990-998.
17. Kolhar P., Anselmo A.C., Gupta V., Pant K., Prabhakarpandian B., Ruoslahti E., Mitragotri S. Using shape effects to target antibody-coated nanoparticles to lung and brain endothelium. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:10753-10758.
18. Fang R.H., Hu C.M., Chen K.N., Luk B.T., Carpenter C.W., Gao W., Li S., Zhang D.E., Lu W., Zhang L. Lipid-insertion enables targeting functionalization of erythrocyte membrane-cloaked nanoparticles. Nanoscale 2013, 5:8884-8888.
19. Matsumura Y., Gotoh M., Muro K., Yamada Y., Shirao K., Shimada Y., Okuwa M., Matsumoto S., Miyata Y., Ohkura H., Chin K., Baba S., Yamao T., Kannami A., Takamatsu Y., Ito K., Takahashi K. Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer. Ann. Oncol. 2004, 15:517-525.
20. Suzuki R., Takizawa T., Kuwata Y., Mutoh M., Ishiguro N., Utoguchi N., Shinohara A., Eriguchi M., Yanagie H., Maruyama K. Effective anti-tumor activity of oxaliplatin encapsulated in transferrin-PEG-liposome. Int. J. Pharm. 2008, 346:143-150.
21. Chen Y.C., Lo C.L., Hsiue G.H. Multifunctional nanomicellar systems for delivering anticancer drugs. J. Biomed. Mater. Res. A 2013, 102:2024-2038.
22. Alexander-Bryant A.A., Vanden Berg-Foels W.S., Wen X. Bioengineering strategies for designing targeted cancer therapies. Adv. Cancer Res. 2013, 118:1-59.
23. Cheng R., Meng F., Deng C., Klok H.A., Zhong Z. Dual and multi-stimuli responsive polymeric nanoparticles for programmed site-specific drug delivery. Biomaterials 2013, 34:3647-3657.
24. Ingber D.E. Tensegrity II. How structural networks influence cellular information processing networks. J. Cell Sci. 2003, 116:1397-1408.
25. Fang H., Declerck Y.A. Targeting the tumor microenvironment: from understanding pathways to effective clinical trials. Cancer Res. 2013, 73:4965-4977.
26. Ingber D.E. Can cancer be reversed by engineering the tumor microenvironment?. Semin. Cancer Biol. 2008, 18:356-364.
27. Allinen M., Beroukhim R., Cai L., Brennan C., Lahti-Domenici J., Huang H., Porter D., Hu M., Chin L., Richardson A., Schnitt S., Sellers W.R., Polyak K. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 2004, 6:17-32.
28. Mueller M.M., Fusenig N.E. Friends or foes - bipolar effects of the tumour stroma in cancer. Nat. Rev. Cancer 2004, 4:839-849.
29. Phillips M.A., Gran M.L., Peppas N.A. Targeted nanodelivery of drugs and diagnostics. Nano Today 2010, 5:143-159.
30. Gu F.X., Karnik R., Wang A.Z., Alexis F., Levy-Nissenbaum E., Hong S., Langer R.S., Farokhzad O.C. Targeted nanoparticles for cancer therapy. Nano Today 2007, 2:14-21.
31. Martinez A., Olmo R., Iglesias I., Teijon J.M., Blanco M.D. Folate-targeted nanoparticles based on albumin and albumin/alginate mixtures as controlled release systems of tamoxifen: synthesis and in vitro characterization. Pharm. Res. 2013, 31:182-193.
32. Lu J., Li Z., Zink J.I., Tamanoi F. In vivo tumor suppression efficacy of mesoporous silica nanoparticles-based drug-delivery system: enhanced efficacy by folate modification. Nanomedicine 2012, 8:212-220.
33. Ponka P., Lok C.N. The transferrin receptor: role in health and disease. Int. J. Biochem. Cell Biol. 1999, 31:1111-1137.
34. Sahoo S.K., Ma W., Labhasetwar V. Efficacy of transferrin-conjugated paclitaxel-loaded nanoparticles in a murine model of prostate cancer. Int. J. Cancer 2004, 112:335-340.
35. Chang J., Paillard A., Passirani C., Morille M., Benoit J.P., Betbeder D., Garcion E. Transferrin adsorption onto PLGA nanoparticles governs their interaction with biological systems from blood circulation to brain cancer cells. Pharm. Res. 2012, 29:1495-1505.
36. Sandoval M.A., Sloat B.R., Lansakara P.D., Kumar A., Rodriguez B.L., Kiguchi K., Digiovanni J., Cui Z. EGFR-targeted stearoyl gemcitabine nanoparticles show enhanced anti-tumor activity. J. Control. Release 2012, 157:287-296.
37. Anhorn M.G., Wagner S., Kreuter J., Langer K., von Briesen H. Specific targeting of HER2 overexpressing breast cancer cells with doxorubicin-loaded trastuzumab-modified human serum albumin nanoparticles. Bioconjug. Chem. 2008, 19:2321-2331.
38. Meng H., Liong M., Xia T., Li Z., Ji Z., Zink J.I., Nel A.E. Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line. ACS Nano 2010, 4:4539-4550.
39. Wang F., Wang Y.C., Dou S., Xiong M.H., Sun T.M., Wang J. Doxorubicin-tethered responsive gold nanoparticles facilitate intracellular drug delivery for overcoming multidrug resistance in cancer cells. ACS Nano 2011, 5:3679-3692.
40. Marrache S., Dhar S. Engineering of blended nanoparticle platform for delivery of mitochondria-acting therapeutics. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:16288-16293.
41. Smith R.A., Porteous C.M., Gane A.M., Murphy M.P. Delivery of bioactive molecules to mitochondria in vivo. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:5407-5412.
42. Bale S.S., Kwon S.J., Shah D.A., Banerjee A., Dordick J.S., Kane R.S. Nanoparticle-mediated cytoplasmic delivery of proteins to target cellular machinery. ACS Nano 2010, 4:1493-1500.
43. Lai P.S., Pai C.L., Peng C.L., Shieh M.J., Berg K., Lou P.J. Enhanced cytotoxicity of saporin by polyamidoamine dendrimer conjugation and photochemical internalization. J. Biomed. Mater. Res. A 2008, 87:147-155.
44. Heitz F., Morris M.C., Divita G. Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics. Br. J. Pharmacol. 2009, 157:195-206.
45. Yu D.H., Lu Q., Xie J., Fang C., Chen H.Z. Peptide-conjugated biodegradable nanoparticles as a carrier to target paclitaxel to tumor neovasculature. Biomaterials 2010, 31:2278-2292.
46. Kim B.Y., Jiang W., Oreopoulos J., Yip C.M., Rutka J.T., Chan W.C. Biodegradable quantum dot nanocomposites enable live cell labeling and imaging of cytoplasmic targets. Nano Lett. 2008, 8:3887-3892.
47. Gratton S.E., Ropp P.A., Pohlhaus P.D., Luft J.C., Madden V.J., Napier M.E., DeSimone J.M. The effect of particle design on cellular internalization pathways. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:11613-11618.
48. Barua S., Yoo J.W., Kolhar P., Wakankar A., Gokarn Y.R., Mitragotri S. Particle shape enhances specificity of antibody-displaying nanoparticles. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:3270-3275.
49. Agarwal R., Singh V., Jurney P., Shi L., Sreenivasan S.V., Roy K. Mammalian cells preferentially internalize hydrogel nanodiscs over nanorods and use shape-specific uptake mechanisms. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:17247-17252.
50. Davis M.E., Zuckerman J.E., Choi C.H., Seligson D., Tolcher A., Alabi C.A., Yen Y., Heidel J.D., Ribas A. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010, 464:1067-1070.
51. Huang Y.H., Bao Y., Peng W., Goldberg M., Love K., Bumcrot D.A., Cole G., Langer R., Anderson D.G., Sawicki J.A. Claudin-3 gene silencing with siRNA suppresses ovarian tumor growth and metastasis. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:3426-3430.
52. Goldberg M.S., Xing D., Ren Y., Orsulic S., Bhatia S.N., Sharp P.A. Nanoparticle-mediated delivery of siRNA targeting Parp1 extends survival of mice bearing tumors derived from Brca1-deficient ovarian cancer cells. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:745-750.
53. Goldberg M.S., Sharp P.A. Pyruvate kinase M2-specific siRNA induces apoptosis and tumor regression. J. Exp. Med. 2012, 209:217-224.
54. Brock A., Krause S., Li H., Kowalski M., Goldberg M.S., Collins J.J., Ingber D.E. Silencing HoxA1 by intraductal injection of siRNA lipidoid nanoparticles prevents mammary tumor progression in mice. Sci. Transl. Med. 2014, 6:217ra212.
55. Sahay G., Querbes W., Alabi C., Eltoukhy A., Sarkar S., Zurenko C., Karagiannis E., Love K., Chen D., Zoncu R., Buganim Y., Schroeder A., Langer R., Anderson D.G. Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling. Nat. Biotechnol. 2013, 31:653-658.
56. Sounni N.E., Noel A. Targeting the tumor microenvironment for cancer therapy. Clin. Chem. 2013, 59:85-93.
57. Ingber D.E., Madri J.A., Jamieson J.D. Role of basal lamina in neoplastic disorganization of tissue architecture. Proc. Natl. Acad. Sci. U. S. A. 1981, 78:3901-3905.
58. Lu P., Weaver V.M., Werb Z. The extracellular matrix: a dynamic niche in cancer progression. J. Cell Biol. 2012, 196:395-406.
59. Zhang J., Liu J. Tumor stroma as targets for cancer therapy. Pharmacol. Ther. 2013, 137:200-215.
60. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv. Enzym. Regul. 2001, 41:189-207.
61. Torchilin V.P. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 2005, 4:145-160.
62. Torchilin V.P. Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J. 2007, 9:E128-E147.
63. Vasir J.K., Labhasetwar V. Targeted drug delivery in cancer therapy. Technol. Cancer Res. Treat. 2005, 4:363-374.
64. Parveen S., Sahoo S.K. Polymeric nanoparticles for cancer therapy. J. Drug Target. 2008, 16:108-123.
65. Claesson-Welsh L. Blood vessels as targets in tumor therapy. Ups. J. Med. Sci. 2012, 117:178-186.
66. Backer M.V., Gaynutdinov T.I., Patel V., Bandyopadhyaya A.K., Thirumamagal B.T., Tjarks W., Barth R.F., Claffey K., Backer J.M. Vascular endothelial growth factor selectively targets boronated dendrimers to tumor vasculature. Mol. Cancer Ther. 2005, 4:1423-1429.
67. Chen J., Wu H., Han D., Xie C. Using anti-VEGF McAb and magnetic nanoparticles as double-targeting vector for the radioimmunotherapy of liver cancer. Cancer Lett. 2006, 231:169-175.
68. Satchi-Fainaro R., Puder M., Davies J.W., Tran H.T., Sampson D.A., Greene A.K., Corfas G., Folkman J. Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nat. Med. 2004, 10:255-261.
69. Satchi-Fainaro R., Mamluk R., Wang L., Short S.M., Nagy J.A., Feng D., Dvorak A.M., Dvorak H.F., Puder M., Mukhopadhyay D., Folkman J. Inhibition of vessel permeability by TNP-470 and its polymer conjugate, caplostatin. Cancer Cell 2005, 7:251-261.
70. Benny O., Fainaru O., Adini A., Cassiola F., Bazinet L., Adini I., Pravda E., Nahmias Y., Koirala S., Corfas G., D'Amato R.J., Folkman J. An orally delivered small-molecule formulation with antiangiogenic and anticancer activity. Nat. Biotechnol. 2008, 26:799-807.
71. Gosk S., Moos T., Gottstein C., Bendas G. VCAM-1 directed immunoliposomes selectively target tumor vasculature in vivo. Biochim. Biophys. Acta 2008, 1778:854-863.
72. Oh P., Borgstrom P., Witkiewicz H., Li Y., Borgstrom B.J., Chrastina A., Iwata K., Zinn K.R., Baldwin R., Testa J.E., Schnitzer J.E. Live dynamic imaging of caveolae pumping targeted antibody rapidly and specifically across endothelium in the lung. Nat. Biotechnol. 2007, 25:327-337.
73. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
74. Hockel M., Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J. Natl. Cancer Inst. 2001, 93:266-276.
75. Iyer A.K., Singh A., Ganta S., Amiji M.M. Role of integrated cancer nanomedicine in overcoming drug resistance. Adv. Drug Deliv. Rev. 2013, 65:1784-1802.
76. Poon Z., Chang D., Zhao X., Hammond P.T. Layer-by-layer nanoparticles with a pH-sheddable layer for in vivo targeting of tumor hypoxia. ACS Nano 2011, 5:4284-4292.
77. Lin Q., Bao C., Yang Y., Liang Q., Zhang D., Cheng S., Zhu L. Highly discriminating photorelease of anticancer drugs based on hypoxia activatable phototrigger conjugated chitosan nanoparticles. Adv. Mater. 2013, 25:1981-1986.
78. Napp J., Behnke T., Fischer L., Wurth C., Wottawa M., Katschinski D.M., Alves F., Resch-Genger U., Schaferling M. Targeted luminescent near-infrared polymer-nanoprobes for in vivo imaging of tumor hypoxia. Anal. Chem. 2011, 83:9039-9046.
79. Simpson-Abelson M.R., Purohit V.S., Pang W.M., Iyer V., Odunsi K., Demmy T.L., Yokota S.J., Loyall J.L., Kelleher R.J., Balu-Iyer S., Bankert R.B. IL-12 delivered intratumorally by multilamellar liposomes reactivates memory T cells in human tumor microenvironments. Clin. Immunol. 2009, 132:71-82.
80. Joshi M.D., Unger W.J., Storm G., van Kooyk Y., Mastrobattista E. Targeting tumor antigens to dendritic cells using particulate carriers. J. Control. Release 2012, 161:25-37.
81. Hamdy S., Haddadi A., Shayeganpour A., Samuel J., Lavasanifar A. Activation of antigen-specific T cell-responses by mannan-decorated PLGA nanoparticles. Pharm. Res. 2011, 28:2288-2301.
82. Brandhonneur N., Chevanne F., Vie V., Frisch B., Primault R., Le Potier M.F., Le Corre P. Specific and non-specific phagocytosis of ligand-grafted PLGA microspheres by macrophages. Eur. J. Pharm. Sci. 2009, 36:474-485.
83. Saraogi G.K., Sharma B., Joshi B., Gupta P., Gupta U.D., Jain N.K., Agrawal G.P. Mannosylated gelatin nanoparticles bearing isoniazid for effective management of tuberculosis. J. Drug Target. 2011, 19:219-227.
84. Espuelas S., Thumann C., Heurtault B., Schuber F., Frisch B. Influence of ligand valency on the targeting of immature human dendritic cells by mannosylated liposomes. Bioconjug. Chem. 2008, 19:2385-2393.
85. He L.Z., Crocker A., Lee J., Mendoza-Ramirez J., Wang X.T., Vitale L.A., O'Neill T., Petromilli C., Zhang H.F., Lopez J., Rohrer D., Keler T., Clynes R. Antigenic targeting of the human mannose receptor induces tumor immunity. J. Immunol. 2007, 178:6259-6267.
86. Romani N., Thurnher M., Idoyaga J., Steinman R.M., Flacher V. Targeting of antigens to skin dendritic cells: possibilities to enhance vaccine efficacy. Immunol. Cell Biol. 2010, 88:424-430.
87. Nguyen D.N., Mahon K.P., Chikh G., Kim P., Chung H., Vicari A.P., Love K.T., Goldberg M., Chen S., Krieg A.M., Chen J., Langer R., Anderson D.G. Lipid-derived nanoparticles for immunostimulatory RNA adjuvant delivery. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:E797-E803.
88. Ali O.A., Huebsch N., Cao L., Dranoff G., Mooney D.J. Infection-mimicking materials to program dendritic cells in situ. Nat. Mater. 2009, 8:151-158.
89. Ali O.A., Doherty E., Bell W.J., Fradet T., Hudak J., Laliberte M.T., Mooney D.J., Emerich D.F. Biomaterial-based vaccine induces regression of established intracranial glioma in rats. Pharm. Res. 2011, 28:1074-1080.
90. Marrache S., Tundup S., Harn D.A., Dhar S. Ex vivo programming of dendritic cells by mitochondria-targeted nanoparticles to produce interferon-gamma for cancer immunotherapy. ACS Nano 2013, 7:7392-7402.
91. Levental K.R., Yu H., Kass L., Lakins J.N., Egeblad M., Erler J.T., Fong S.F., Csiszar K., Giaccia A., Weninger W., Yamauchi M., Gasser D.L., Weaver V.M. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 2009, 139:891-906.
92. Huang S., Ingber D.E. Cell tension, matrix mechanics, and cancer development. Cancer Cell 2005, 8:175-176.
93. Xiao Q., Ge G. Lysyl oxidase, extracellular matrix remodeling and cancer metastasis. Cancer Microenviron. 2012, 5:261-273.
94. Rodriguez C., Rodriguez-Sinovas A., Martinez-Gonzalez J. Lysyl oxidase as a potential therapeutic target. Drug News Perspect. 2008, 21:218-224.
95. Ng M.R., Brugge J.S. A stiff blow from the stroma: collagen crosslinking drives tumor progression. Cancer Cell 2009, 16:455-457.
96. Kanapathipillai M., Mammoto A., Mammoto T., Kang J.H., Jiang E., Ghosh K., Korin N., Gibbs A., Mannix R., Ingber D.E. Inhibition of mammary tumor growth using lysyl oxidase-targeting nanoparticles to modify extracellular matrix. Nano Lett. 2012, 12:3213-3217.
97. Platt V.M., Szoka F.C. Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor. Mol. Pharm. 2008, 5:474-486.
98. Misra S., Heldin P., Hascall V.C., Karamanos N.K., Skandalis S.S., Markwald R.R., Ghatak S. Hyaluronan-CD44 interactions as potential targets for cancer therapy. FEBS J. 2011, 278:1429-1443.
99. Yadav A.K., Mishra P., Mishra A.K., Mishra P., Jain S., Agrawal G.P. Development and characterization of hyaluronic acid-anchored PLGA nanoparticulate carriers of doxorubicin. Nanomedicine 2007, 3:246-257.
100. Hyung W., Ko H., Park J., Lim E., Park S.B., Park Y.J., Yoon H.G., Suh J.S., Haam S., Huh Y.M. Novel hyaluronic acid (HA) coated drug carriers (HCDCs) for human breast cancer treatment. Biotechnol. Bioeng. 2008, 99:442-454.
101. Lee T., Lim E.K., Lee J., Kang B., Choi J., Park H.S., Suh J.S., Huh Y.M., Haam S. Efficient CD44-targeted magnetic resonance imaging (MRI) of breast cancer cells using hyaluronic acid (HA)-modified MnFe2O4 nanocrystals. Nanoscale Res. Lett. 2013, 8:149.
102. Eikenes L., Tari M., Tufto I., Bruland O.S., de Lange Davies C. Hyaluronidase induces a transcapillary pressure gradient and improves the distribution and uptake of liposomal doxorubicin (Caelyx) in human osteosarcoma xenografts. Br. J. Cancer 2005, 93:81-88.
103. Scodeller P., Catalano P.N., Salguero N., Duran H., Wolosiuk A., Soler-Illia G.J. Hyaluronan degrading silica nanoparticles for skin cancer therapy. Nanoscale 2013, 5:9690-9698.
104. Goodman T.T., Olive P.L., Pun S.H. Increased nanoparticle penetration in collagenase-treated multicellular spheroids. Int. J. Nanomedicine 2007, 2:265-274.
105. Liu Q., Li R.T., Qian H.Q., Yang M., Zhu Z.S., Wu W., Qian X.P., Yu L.X., Jiang X.Q., Liu B.R. Gelatinase-stimuli strategy enhances the tumor delivery and therapeutic efficacy of docetaxel-loaded poly(ethylene glycol)-poly(varepsilon-caprolactone) nanoparticles. Int. J. Nanomedicine 2012, 7:281-295.
106. Decitre M., Gleyzal C., Raccurt M., Peyrol S., Aubert-Foucher E., Csiszar K., Sommer P. Lysyl oxidase-like protein localizes to sites of de novo fibrinogenesis in fibrosis and in the early stromal reaction of ductal breast carcinomas. Lab. Invest. 1998, 78:143-151.
107. Wiseman B.S., Werb Z. Stromal effects on mammary gland development and breast cancer. Science 2002, 296:1046-1049.
108. Akiri G., Sabo E., Dafni H., Vadasz Z., Kartvelishvily Y., Gan N., Kessler O., Cohen T., Resnick M., Neeman M., Neufeld G. Lysyl oxidase-related protein-1 promotes tumor fibrosis and tumor progression in vivo. Cancer Res. 2003, 63:1657-1666.
109. Alowami S., Troup S., Al-Haddad S., Kirkpatrick I., Watson P.H. Mammographic density is related to stroma and stromal proteoglycan expression. Breast Cancer Res. 2003, 5:R129-R135.
110. Eshchenko T.Y., Rykova V.I., Chernakov A.E., Sidorov S.V., Grigorieva E.V. Expression of different proteoglycans in human breast tumors. Biochemistry 2007, 72:1016-1020.
111. Bischof A.G., Yuksel D., Mammoto T., Mammoto A., Krause S., Ingber D.E. Breast cancer normalization induced by embryonic mesenchyme is mediated by extracellular matrix biglycan. Integr. Biol. 2013, 5:1045-1056.
112. Magzoub M., Jin S., Verkman A.S. Enhanced macromolecule diffusion deep in tumors after enzymatic digestion of extracellular matrix collagen and its associated proteoglycan decorin. FASEB J. 2008, 22:276-284.
113. Ulisse S., Baldini E., Sorrenti S., D'Armiento M. The urokinase plasminogen activator system: a target for anti-cancer therapy. Curr. Cancer Drug Targets 2009, 9:32-71.
114. Kessenbrock K., Plaks V., Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010, 141:52-67.
115. Kondo M., Asai T., Katanasaka Y., Sadzuka Y., Tsukada H., Ogino K., Taki T., Baba K., Oku N. Anti-neovascular therapy by liposomal drug targeted to membrane type-1 matrix metalloproteinase. Int. J. Cancer 2004, 108:301-306.
116. Mansour A.M., Drevs J., Esser N., Hamada F.M., Badary O.A., Unger C., Fichtner I., Kratz F. A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2. Cancer Res. 2003, 63:4062-4066.
117. Kim G.B., Kim K.H., Park Y.H., Ko S., Kim Y.P. Colorimetric assay of matrix metalloproteinase activity based on metal-induced self-assembly of carboxy gold nanoparticles. Biosens. Bioelectron. 2013, 41:833-839.
118. Sun I.C., Eun D.K., Koo H., Ko C.Y., Kim H.S., Yi D.K., Choi K., Kwon I.C., Kim K., Ahn C.H. Tumor-targeting gold particles for dual computed tomography/optical cancer imaging. Angew. Chem. 2011, 50:9348-9351.
119. Suresh A.K.W., Weng Y., Li Z., Zerda R., Van Haute D., Williams J.C., Berlin J.M. Matrix metalloproteinase-triggered denuding of engineered gold nanoparticles for selective cell uptake. J. Mater. Chem. B 2013, 1:2341-2349.
120. Chen W.H., Xu X.D., Jia H.Z., Lei Q., Luo G.F., Cheng S.X., Zhuo R.X., Zhang X.Z. Therapeutic nanomedicine based on dual-intelligent functionalized gold nanoparticles for cancer imaging and therapy in vivo. Biomaterials 2013, 34:8798-8807.
121. Hansen L., Unmack Larsen E.K., Nielsen E.H., Iversen F., Liu Z., Thomsen K., Pedersen M., Skrydstrup T., Nielsen N.C., Ploug M., Kjems J. Targeting of peptide conjugated magnetic nanoparticles to urokinase plasminogen activator receptor (uPAR) expressing cells. Nanoscale 2013, 5:8192-8201.
122. Yang L., Peng X.H., Wang Y.A., Wang X., Cao Z., Ni C., Karna P., Zhang X., Wood W.C., Gao X., Nie S., Mao H. Receptor-targeted nanoparticles for in vivo imaging of breast cancer. Clin. Cancer Res. 2009, 15:4722-4732.
123. Tan M., Wu X., Jeong E.K., Chen Q., Lu Z.R. Peptide-targeted Nanoglobular Gd-DOTA monoamide conjugates for magnetic resonance cancer molecular imaging. Biomacromolecules 2010, 11:754-761.
124. Hoffman J.A., Giraudo E., Singh M., Zhang L., Inoue M., Porkka K., Hanahan D., Ruoslahti E. Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma. Cancer Cell 2003, 4:383-391.
125. Simberg D., Duza T., Park J.H., Essler M., Pilch J., Zhang L., Derfus A.M., Yang M., Hoffman R.M., Bhatia S., Sailor M.J., Ruoslahti E. Biomimetic amplification of nanoparticle homing to tumors. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:932-936.
126. Milane L., Ganesh S., Shah S., Duan Z.F., Amiji M. Multi-modal strategies for overcoming tumor drug resistance: hypoxia, the Warburg effect, stem cells, and multifunctional nanotechnology. J. Control. Release 2011, 155:237-247.
127. Davis M.E., Chen Z.G., Shin D.M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov. 2008, 7:771-782.
128. Shen F., Chu S., Bence A.K., Bailey B., Xue X., Erickson P.A., Montrose M.H., Beck W.T., Erickson L.C. Quantitation of doxorubicin uptake, efflux, and modulation of multidrug resistance (MDR) in MDR human cancer cells. J. Pharmacol. Exp. Ther. 2008, 324:95-102.
129. Pepin X., Attali L., Domrault C., Gallet S., Metreau J.M., Reault Y., Cardot P.J., Imalalen M., Dubernet C., Soma E., Couvreur P. On the use of ion-pair chromatography to elucidate doxorubicin release mechanism from polyalkylcyanoacrylate nanoparticles at the cellular level. J. Chromatogr. B Biomed. Sci. Appl. 1997, 702:181-191.
130. Vauthier C., Dubernet C., Chauvierre C., Brigger I., Couvreur P. Drug delivery to resistant tumors: the potential of poly(alkyl cyanoacrylate) nanoparticles. J. Control. Release 2003, 93:151-160.
131. Lee E.S., Na K., Bae Y.H. Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor. J. Control. Release 2005, 103:405-418.
132. Miao J., Du Y.Z., Yuan H., Zhang X.G., Hu F.Q. Drug resistance reversal activity of anticancer drug loaded solid lipid nanoparticles in multi-drug resistant cancer cells. Colloids Surf. B: Biointerfaces 2013, 110:74-80.
133. Iangcharoen P., Punfa W., Yodkeeree S., Kasinrerk W., Ampasavate C., Anuchapreeda S., Limtrakul P. Anti-P-glycoprotein conjugated nanoparticles for targeting drug delivery in cancer treatment. Arch. Pharm. Res. 2011, 34:1679-1689.
134. Nazir S., Hussain T., Ayub A., Rashid U., Macrobert A.J. Nanomaterials in combating cancer: therapeutic applications and developments. Nanomedicine 2013, 10:19-34.
135. Vaishnaw A.K., Gollob J., Gamba-Vitalo C., Hutabarat R., Sah D., Meyers R., de Fougerolles T., Maraganore J. A status report on RNAi therapeutics. Silence 2010, 1:14.
136. Dong X., Mumper R.J. Nanomedicinal strategies to treat multidrug-resistant tumors: current progress. Nanomedicine (London) 2010, 5:597-615.
137. Willingham S.B., Volkmer J.P., Gentles A.J., Sahoo D., Dalerba P., Mitra S.S., Wang J., Contreras-Trujillo H., Martin R., Cohen J.D., Lovelace P., Scheeren F.A., Chao M.P., Weiskopf K., Tang C., Volkmer A.K., Naik T.J., Storm T.A., Mosley A.R., Edris B., Schmid S.M., Sun C.K., Chua M.S., Murillo O., Rajendran P., Cha A.C., Chin R.K., Kim D., Adorno M., Raveh T., Tseng D., Jaiswal S., Enger P.O., Steinberg G.K., Li G., So S.K., Majeti R., Harsh G.R., van de Rijn M., Teng N.N., Sunwoo J.B., Alizadeh A.A., Clarke M.F., Weissman I.L. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:6662-6667.
138. Rodriguez P.L., Harada T., Christian D.A., Pantano D.A., Tsai R.K., Discher D.E. Minimal "Self" peptides that inhibit phagocytic clearance and enhance delivery of nanoparticles. Science 2013, 339:971-975.
139. Pinheiro A.V., Han D., Shih W.M., Yan H. Challenges and opportunities for structural DNA nanotechnology. Nat. Nanotechnol. 2011, 6:763-772.
140. Lu C.H., Willner B., Willner I. DNA nanotechnology: from sensing and DNA machines to drug-delivery systems. ACS Nano 2013, 7:8320-8332.
141. Douglas S.M., Bachelet I., Church G.M. A logic-gated nanorobot for targeted transport of molecular payloads. Science 2012, 335:831-834.
142. Oloumi A., Lam W., Banath J.P., Olive P.L. Identification of genes differentially expressed in V79 cells grown as multicell spheroids. Int. J. Radiat. Biol. 2002, 78:483-492.
143. Kim S.H., Kuh H.J., Dass C.R. The reciprocal interaction: chemotherapy and tumor microenvironment. Curr. Drug Discov. Technol. 2011, 8:102-106.
144. Albanese A., Lam A.K., Sykes E.A., Rocheleau J.V., Chan W.C. Tumour-on-a-chip provides an optical window into nanoparticle tissue transport. Nat. Commun. 2013, 4:2718.
145. Huh D., Matthews B.D., Mammoto A., Montoya-Zavala M., Hsin H.Y., Ingber D.E. Reconstituting organ-level lung functions on a chip. Science 2010, 328:1662-1668.
146. Huh D., Leslie D.C., Matthews B.D., Fraser J.P., Jurek S., Hamilton G.A., Thorneloe K.S., McAlexander M.A., Ingber D.E. A human disease model of drug toxicity-induced pulmonary edema in a lung-on-a-chip microdevice. Sci. Transl. Med. 2012, 4:159ra147.
147. DeCosse J.J., Gossens C.L., Kuzma J.F., Unsworth B.R. Breast cancer: induction of differentiation by embryonic tissue. Science 1973, 181:1057-1058.
148. Ingber D.E., Madri J.A., Jamieson J.D. Basement membrane as a spatial organizer of polarized epithelia. Exogenous basement membrane reorients pancreatic epithelial tumor cells in vitro. Am. J. Pathol. 1986, 122:129-139.
149. Liedl T., Hogberg B., Tytell J., Ingber D.E., Shih W.M. Self-assembly of three-dimensional prestressed tensegrity structures from DNA. Nat. Nanotechnol. 2010, 5:520-524.